Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979622 | 0.84 | MMP2 (0.50) | ALDH1A1HPGDMMP2MMP3MAOB | |
| SCHEMBL12461736 | 0.82 | MMP2 (0.49) | ALDH1A1HPGDMMP2MMP3MAOB | |
| SCHEMBL28239561 | 0.82 | MMP2 (0.49) | ALDH1A1HPGDMMP2MMP3MAOB | |
| SCHEMBL868642 | 0.81 | MMP2 (0.54) | ALDH1A1HPGDMMP2MMP3MAOB | |
| SCHEMBL24450219 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HPGDMMP2MMP3MAOB | |
| SCHEMBL8436281 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDMMP2MMP3MAOB | |
| SCHEMBL5663771 | 0.79 | SIGMAR1 (0.53) | ALDH1A1MAOBRAB9AMAPK1 | |
| SCHEMBL5661525 | 0.79 | SIGMAR1 (0.53) | ALDH1A1MAOBRAB9AMAPK1 | |
| SCHEMBL21386579 | 0.79 | MMP2 (0.57) | ALDH1A1HPGDMMP2MMP3HRH3 | |
| SCHEMBL9146899 | 0.79 | MMP2 (0.57) | ALDH1A1HPGDMMP2MMP3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| CN-100579957-C | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2010-01-13 | — | — | CN | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| CN-1642906-A | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | ALDH1A1 2071/4885HPGD 4285/4885MMP2 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.